journal
MENU ▼
Read by QxMD icon Read
search

Neurodegenerative Disease Management

journal
https://www.readbyqxmd.com/read/28534719/activation-of-nrf2-signaling-as-a-common-treatment-of-neurodegenerative-diseases
#1
Albena T Dinkova-Kostova, Aleksey G Kazantsev
No abstract text is available yet for this article.
May 23, 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28534696/light-sleep-and-circadian-rhythms-in-older-adults-with-alzheimer-s-disease-and-related-dementias
#2
Mariana G Figueiro
Alzheimer's disease and related dementias (ADRD) can cause sleep and behavioral problems that are problematic for ADRD patients and their family caregivers. Light therapy has shown promise as a nonpharmacological treatment, and preliminary studies demonstrate that timed light exposure can consolidate and improve nighttime sleep efficiency, increase daytime wakefulness and reduce evening agitation without the adverse effects of pharmacological solutions. Compliance with light treatment and the accurate measurement of light exposures during treatment, however, have presented barriers for the adoption of light therapy for ADRD...
May 23, 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28445082/the-impact-of-%C3%AE-amyloid-positron-emission-tomography-on-the-diagnostic-and-treatment-decisions-of-dementia-experts
#3
Michael L Ganz, Alie F Tawah, Shien Guo, Abhishek S Chitnis, Hedwig Silies, Barbara Schäuble, Aleksandar Jovalekic, Norman L Foster
AIM: Amyloid positron emission tomography (aPET) measurement of Alzheimer's disease (AD) pathology could improve the accurate diagnosis of cognitive disorders. Appropriate use criteria recommend that only dementia experts order aPET. MATERIALS & METHODS: We surveyed 145 dementia experts about their current approaches to evaluation and treatment and the likely influence of aPET. RESULTS: Experts expected aPET to alter diagnostic procedures and patient management and also increase diagnostic certainty...
April 26, 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28540772/management-of-glaucoma-as-a-neurodegenerative-disease
#4
Gurjeet Jutley, Sheila Mh Luk, Mohammad H Dehabadi, M Francesca Cordeiro
Glaucoma is a neurodegenerative disease with an estimated prevalence of 60 million people, and the most common cause of irreversible blindness worldwide. The mainstay of treatment has been aimed at lowering intraocular pressure, currently the only modifiable risk factor. Unfortunately, despite adequate pressure control, many patients go on to suffer irreversible visual loss. We first briefly examine currently established intraocular pressure lowering-treatments, with a discussion of their roles in neuroprotection as demonstrated by both animal and clinical studies...
April 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28540771/identifying-therapeutic-targets-for-alzheimer-s-disease-with-big-data
#5
Nilüfer Ertekin-Taner
Nilüfer Ertekin-Taner is a Professor of Neuroscience and Neurology at the Mayo Clinic, Jacksonville, FL, USA. A neurogeneticist and board-certified behavioral neurologist, she received her medical degree from Hacettepe University Medical School in Ankara, Turkey and her doctorate degree in Molecular Neuroscience from Mayo Graduate School. She completed her residency training in the Department of Neurology at Mayo Clinic in Rochester (MN, USA) and fellowship in Behavioral Neurology at Mayo Clinic in Jacksonville...
April 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28128039/introducing-a-new-volume-of-neurodegenerative-disease-management
#6
Laura Dormer
No abstract text is available yet for this article.
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28120630/a-randomized-fixed-dose-dose-response-study-of-ropinirole-prolonged-release-in-advanced-parkinson-s-disease
#7
Theresa A Zesiewicz, Stephen Chriscoe, Theresa Jimenez, James Upward, Maria Davy, Susan VanMeter
AIM: This Phase IV, double-blind, randomized, parallel-group study characterized the dose-response and tolerability of fixed doses of ropinirole prolonged release (PR) in subjects with advanced Parkinson's disease. PATIENTS & METHODS: Subjects receiving concomitant l-dopa received once-daily ropinirole PR 4, 8, 12, 16 or 24 mg, or placebo, up-titrated for 13 weeks, maintained for 4 weeks. RESULTS: At maintenance period week 4, ropinirole PR significantly reduced total awake 'Off-time' (16 mg; p = 0...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28120629/a-fixed-dose-dose-response-study-of-ropinirole-prolonged-release-in-early-stage-parkinson-s-disease
#8
Theresa A Zesiewicz, Stephen Chriscoe, Theresa Jimenez, James Upward, Susan VanMeter
AIM: This Phase IV, double-blind, randomized, parallel-group study characterized the dose-response and tolerability of fixed doses of ropinirole prolonged release (PR). PATIENTS & METHODS: Subjects with early Parkinson's disease (PD) received placebo or ropinirole PR 2, 4, 8, 12 or 24 mg once daily, up-titrated to randomized or highest tolerated dose, maintained for 4 weeks. RESULTS: The primary end point was not met (change from baseline in Unified PD Rating Scale motor score)...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28097926/a-pilot-study-of-a-minimally-supervised-home-exercise-and-walking-program-for-people-with-parkinson-s-disease-in-jordan
#9
Hanan Khalil, Monica Busse, Lori Quinn, Mohammad Nazzal, Waleed Batyha, Shatha Alkhazaleh, Mahmoud A Alomari
AIM: This study aimed to evaluate the feasibility and cultural considerations of a minimally supervised, home-based exercise program in Jordan. METHODS: Quantitative and qualitative approaches were used. Thirty participants were randomly allocated to either an 8-week intervention group (n = 16), or a standard care group (n = 14). The intervention incorporated the home use of an exercise DVD, walking program and initial instructional sessions and weekly phone calls provided by a physiotherapist...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28074683/objectively-measured-sedentary-behavior-and-brain-volumetric-measurements-in-multiple-sclerosis
#10
Rachel E Klaren, Elizabeth A Hubbard, Nathan C Wetter, Bradley P Sutton, Robert W Motl
AIM: This study examined the association between sedentary behavior patterns and whole brain gray matter (GM), white matter (WM) and subcortical GM structures in persons with multiple sclerosis (MS). METHODS: 36 persons with MS wore an accelerometer and underwent a brain MRI. Whole brain GM and WM and deep GM structures were calculated from 3D T1-weighted structural brain images. RESULTS: There were statistically significant (p < 0.01) and moderate or large associations between number of sedentary bouts/day and brain volume measures...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28074678/prevention-of-alzheimer-s-disease-cerebrovascular-disease-and-dementia-in-women-the-case-for-menopause-hormone-therapy
#11
Dennis A Davey
Alzheimer's disease, cerebrovascular disease and aging-related cognitive impairment and dementia (ARCID) increase in prevalence in women with advancing age. The development of Alzheimer's disease, cerebrovascular disease and ARCID may be postponed or prevented by protective measures including the active treatment of vascular risk factors and continuing exercise and healthy lifestyle from early- and mid-life onward. Bilateral oophorectomy before the natural menopause is associated with an increased incidence of ARCID and the increased risk is significantly reduced by estrogen therapy...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28071330/subcutaneous-peginterferon-%C3%AE-1a-injection-site-reaction-experience-and-mitigation-delphi-analysis-of-the-allow-study
#12
Barry Hendin, DeRen Huang, Sibyl Wray, Robert T Naismith, Sheri Rosenblatt, Javier Zambrano, Brian Werneburg
AIM: The objective of this Delphi analysis was to obtain consensus on injection-site reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial using a three-step approach. METHODS: Study investigators and coordinators from investigative sites enrolling four or more patients in ALLOW participated in three rounds of questionnaires and interviews...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28071266/biogen-s-portfolio-and-research-efforts-in-multiple-sclerosis-an-interview-with-dr-ralph-kern
#13
Ralph Kern
Ralph Kern speaks to Laura Dormer, Commissioning Editor: Dr Ralph Kern is Senior Vice President and Head of Worldwide Medical at Biogen in Cambridge, MA, USA. In this role, he oversees Biogen's global therapeutic, regional and country medical teams, global medical operations, as well as medical research and scientific communications functions. Prior to joining Biogen, he was head of the Neuroscience Medical Unit at Novartis Pharmaceuticals Corporation and held various medical and commercial leadership roles at Genzyme Corporation...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/27937746/teriflunomide-in-multiple-sclerosis-an-update
#14
Aaron E Miller
Teriflunomide, a once-daily, oral disease-modifying therapy, has demonstrated efficacy in patients with relapsing forms of multiple sclerosis (MS) and patients with a first clinical episode suggestive of MS. As the only disease-modifying therapy with positive disability results in two Phase III trials, teriflunomide significantly slowed disability in patients with relapsing forms of MS. We highlight data from the Phase II study and the TEMSO, TOWER, TOPIC and TENERE teriflunomide studies. TEMSO MRI outcomes have been supported with Structural Image Evaluation Using Normalization of Atrophy analyses...
February 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/28112008/measuring-disease-activity-and-clinical-response-during-maintenance-therapy-in-cidp-from-ice-trial-outcome-measures-to-future-clinical-biomarkers
#15
Hans D Katzberg, Norman Latov, Francis O Walker
Some patients with chronic inflammatory demyelinating polyradiculoneuropathy who respond to initial intravenous immunoglobulin require repeated courses over prolonged periods of time; however, evidence to guide dosage and interval of intravenous immunoglobulin during maintenance therapy is limited. Optimizing treatment requires assessment of underlying disease activity and clinical outcome. Electrophysiological measures of demyelination, and clinical measures using handgrip strength and walking velocity promise to be particularly informative...
January 23, 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/27879155/managing-cognition-in-progressive-supranuclear-palsy
#16
Timothy Rittman, Ian Ts Coyle-Gilchrist, James B Rowe
Cognitive impairment is integral to the syndrome of progressive supranuclear palsy. It is most commonly described as a frontal dysexecutive syndrome but other impairments include apathy, impulsivity, visuospatial and memory functions. Cognitive dysfunction may be exacerbated by mood disturbance, medication and communication problems. In this review we advocate an individualized approach to managing cognitive impairment in progressive supranuclear palsy with the education of caregivers as a central component...
December 2016: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/27874500/rehabilitation-in-multiple-sclerosis-the-role-of-tele-rehabilitation-gaming
#17
Mathias Mäurer
No abstract text is available yet for this article.
December 2016: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/27874499/muscle-elastography-in-multiple-sclerosis-spasticity
#18
Giovanni Illomei
Ultrasound elastography is a novel imaging modality for evaluating the elasticity of biological tissues. The technique is widely used in oncology to detect and differentiate malignant lesions in soft tissues. Studies have explored use of ultrasound elastography to measure the mechanical properties of muscle in patients with multiple sclerosis spasticity. Real-time elastography was shown to correlate well with subjective scales commonly used to measure MS spasticity. Ultrasound elastography has the potential to become a new objective gold standard to monitor symptom evolution in patients with MS spasticity and to evaluate the efficacy of antispasticity treatment...
December 2016: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/27874498/what-is-new-in-multiple-sclerosis-spasticity-research-poster-session-highlights
#19
Angelo Ghezzi
Each year at the MS Experts Summit, relevant research in the field of multiple sclerosis spasticity is featured in poster sessions. In 2016, six new studies were presented.
December 2016: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/27874497/country-breakout-session-highlights
#20
Angelo Ghezzi, Linard Filli, Claudio Solaro, Claude Mekies, Lamberto Landete, Jan Lycke
At the 2016 MS Experts Summit, country-relevant aspects pertaining to the management of symptoms and disability in multiple sclerosis (MS), with emphasis on those associated with spasticity, were explored in interactive country breakout sessions chaired by selected MS experts. Attendees had the opportunity to review and discuss topics in their own native language. After feedback from each session leader, key messages were collated and presented in a Plenary Session by Summit chair, Professor Angelo Ghezzi. Topics at this year's Summit included: gait tracking (Germany/Switzerland); the Care Alliance against MS spasticity (Italy); MS spasticity and associated symptoms (France); improvement in MS symptoms and functionality and patients' independence (Spain); Swedish MS guidelines (Sweden/Rest of World)...
December 2016: Neurodegenerative Disease Management
journal
journal
42631
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"